| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab096516-10μl |
10μl |
现货  |
| |
| Ab096516-50μl |
50μL |
现货 |
| |
| Ab096516-100μl |
100μL |
期货 |
| |
| Ab096516-1ml |
1ml |
期货 |
|
| 产品名称 | cIAP2 Mouse mAb |
|---|---|
| 别名 | 含杆状病毒IAP重复蛋白3(BIRC3)单克隆抗体 | cIAP2小鼠单克隆抗体 | cIAP2小鼠单抗 |
| 英文别名 | AIP 1 antibody | AIP1 antibody | API 2 antibody | API2 antibody | Apoptosis inhibitor 2 antibody | Baculoviral IAP repeat containing 3antibody | Baculoviral IAP repeat containing protein 3 antibody | Baculoviral IAP repeat-containing protein 3 antibody | |
| 规格或纯度 | ExactAb™, Validated, 1.0 mg/mL |
| 宿主种属 | 小鼠(Mouse) |
| 特异性 | BIRC3 |
| 种属反应性 | 人(Human),猴(Monkey) |
| 免疫原 | Purified recombinant human c-IAP2 protein fragments expressed in E.coli (AA 25-267). |
| 阳性对照 | WB: Ramos, MCF7 and HeLa cell lysates. |
| 偶联 | Unconjugated |
| 克隆类型 | 单克隆抗体 |
|---|---|
| 克隆号 | 1F12-E5-G12 |
| Format | Whole IgG |
| 亚型 | Mouse IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 150 kDa |
| 纯化方法 | Protein G purified |
| 物理外观 | Liquid |
| 储存缓冲液 | 10mM PBS, 50% Glycerol, 0.5% BSA, 0.02% Sodium azide, pH 7.3 |
| 防腐剂 | 0.02% Sodium azide |
| 浓度 | 1.0 mg/mL |
| 储存温度 | -20°C储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 4°C 短期储存（1-2 周）。-20°C下长期保存（24个月）。收货后建议分装。避免冷冻/解冻循环。 |
| 分子类型 | 抗体 |
cIAP2 Mouse mAb (Ab096516) - Western Blot
All lanes: cIAP2 Mouse mAb (Ab096516) at 1/2000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Mouse IgG H&L (HRP) (Ab138044) at 1/20000 dilution
Predicted band size: 68 kDa
Observed band size: 76, 79 kDa
Exposure time: 50.9 s
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 应用名称 | 稀释比例 |
|---|---|
| WB | 1/500-1/2000 |
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F0102427 |
分析证书 | 24-01-15 | Ab096516 |
| ZJ24F0102428 |
分析证书 | 24-01-15 | Ab096516 |
¥499.90
| 1. Gyrd-Hansen M, Meier P. (2010) IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.. Nat Rev Cancer, 10 (8): (561-74). [PMID:20651737] |
| 2. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R et al.. (2011) A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.. J Med Chem, 54 (8): (2714-26). [PMID:21443232] |
| 3. Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG et al.. (2012) Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).. J Med Chem, 55 (9): (4101-13). [PMID:22413863] |
| 4. Sato S, Aoyama H, Miyachi H, Naito M, Hashimoto Y.. (2008) Demonstration of direct binding of cIAP1 degradation-promoting bestatin analogs to BIR3 domain: Synthesis and application of fluorescent bestatin ester analogs.. Bioorg Med Chem Lett, 18 (11): (3354-3358). [PMID:18448338] [10.1016/j.bmcl.2008.04.031] |
| 5. Zhang B, Nikolovska-Coleska Z, Zhang Y, Bai L, Qiu S, Yang CY, Sun H, Wang S, Wu Y.. (2008) Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases.. J Med Chem, 51 (23): (7352-7355). [PMID:19012392] [10.1021/jm801146d] |
| 6. Sun W, Nikolovska-Coleska Z, Qin D, Sun H, Yang CY, Bai L, Qiu S, Wang Y, Ma D, Wang S.. (2009) Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases.. J Med Chem, 52 (3): (593-596). [PMID:19138149] [10.1021/jm801101z] |
| 7. Sun H, Liu L, Lu J, Qiu S, Yang CY, Yi H, Wang S.. (2010) Cyclopeptide Smac mimetics as antagonists of IAP proteins.. Bioorg Med Chem Lett, 20 (10): (3043-3046). [PMID:20443226] [10.1016/j.bmcl.2010.03.114] |
| 8. Sun H, Liu L, Lu J, Bai L, Li X, Nikolovska-Coleska Z, McEachern D, Yang CY, Qiu S, Yi H, Sun D, Wang S.. (2011) Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.. J Med Chem, 54 (9): (3306-3318). [PMID:21462933] [10.1021/jm101651b] |
| 9. Sheng R, Sun H, Liu L, Lu J, McEachern D, Wang G, Wen J, Min P, Du Z, Lu H, Kang S, Guo M, Yang D, Wang S.. (2013) A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.. J Med Chem, 56 (10): (3969-3979). [PMID:23651223] [10.1021/jm400216d] |
| 10. Kester RF, Donnell AF, Lou Y, Remiszewski SW, Lombardo LJ, Chen S, Le NT, Lo J, Moliterni JA, Han X, Hogg JH, Liang W, Michoud C, Rupert KC, Mischke S, Le K, Weisel M, Janson CA, Lukacs CM, Fretland AJ, Hong K, Polonskaia A, Gao L, Li S, Solis DS, Aguilar D, Tardell C, Dvorozniak M, Tannu S, Lee EC, Schutt AD, Goggin B.. (2013) Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.. J Med Chem, 56 (20): (7788-7803). [PMID:24093940] [10.1021/jm400732v] |
| 11. Zhang Y, Seigal BA, Terrett NK, Talbott RL, Fargnoli J, Naglich JG, Chaudhry C, Posy SL, Vuppugalla R, Cornelius G, Lei M, Wang C, Zhang Y, Schmidt RJ, Wei DD, Miller MM, Allen MP, Li L, Carter PH, Vite GD, Borzilleri RM.. (2015) Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of Cancer.. ACS Med Chem Lett, 6 (7): (770-775). [PMID:26191364] [10.1021/acsmedchemlett.5b00091] |
| 12. Abdel-Magid AF.. (2016) MALT1 Inhibitors May Potentially Treat Lymphomas and Autoimmune Disorders.. ACS Med Chem Lett, 7 (3): (205-206). [PMID:26985302] [10.1021/acsmedchemlett.6b00015] |
| 13. Tomoshige S, Nomura S, Ohgane K, Hashimoto Y, Ishikawa M.. (2018) Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative.. Bioorg Med Chem Lett, 28 (4): (707-710). [PMID:29366651] [10.1016/j.bmcl.2018.01.012] |
| 14. Baggio C, Gambini L, Udompholkul P, Salem AF, Aronson A, Dona A, Troadec E, Pichiorri F, Pellecchia M.. (2018) Design of Potent pan-IAP and Lys-Covalent XIAP Selective Inhibitors Using a Thermodynamics Driven Approach.. J Med Chem, 61 (14): (6350-6363). [PMID:29940121] [10.1021/acs.jmedchem.8b00810] |
| 15. Pissot Soldermann C,Simic O,Renatus M,Erbel P,Melkko S,Wartmann M,Bigaud M,Weiss A,McSheehy P,Endres R,Santos P,Blank J,Schuffenhauer A,Bold G,Buschmann N,Zoller T,Altmann E,Manley PW,Dix I,Buchdunger E,Scesa J,Quancard J,Schlapbach A,Bornancin F,Radimerski T,Régnier CH. (2020) Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing.. J Med Chem, 63 (23): (14576-14593). [PMID:33252239] [10.1021/acs.jmedchem.0c01245] |
| 16. Rothe, M M, Pan, M G MG, Henzel, W J WJ, Ayres, T M TM and Goeddel, D V DV.. (1995) The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins.. Cell, (29): [PMID:8548810] |
| 17. Liston, P P and 10 more authors.. (1996) Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes.. Nature, (25): [PMID:8552191] |
| 18. Uren, A G AG, Pakusch, M M, Hawkins, C J CJ, Puls, K L KL and Vaux, D L DL.. (1996) Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors.. Proceedings of the National Academy of Sciences of the United States of America, (14): [PMID:8643514] |
| 19. Horrevoets, A J AJ and 5 more authors.. (1999) Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes.. Blood, (15): [PMID:10233894] |
| 20. Baens, M M, Steyls, A A, Dierlamm, J J, De Wolf-Peeters, C C and Marynen, P P.. (2000) Structure of the MLT gene and molecular characterization of the genomic breakpoint junctions in the t(11;18)(q21;q21) of marginal zone B-cell lymphomas of MALT type.. Genes, chromosomes & cancer, [PMID:11066071] |
| 21. Samuel, Temesgen T and 5 more authors.. (2005) cIAP1 Localizes to the nuclear compartment and modulates the cell cycle.. Cancer research, (1): [PMID:15665297] |
| 22. Zobel, Kerry K and 10 more authors.. (2006) Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.. ACS chemical biology, (19): [PMID:17168540] |
| 23. Dubrez-Daloz, Laurence L, Dupoux, Alban A and Cartier, Jessy J.. (2008) IAPs: more than just inhibitors of apoptosis proteins.. Cell cycle (Georgetown, Tex.), (15): [PMID:18414036] |
| 24. Ndubaku, Chudi C and 15 more authors.. (2009) Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists.. ACS chemical biology, (17): [PMID:19492850] |
| 25. Lopez, Juanita J and Meier, Pascal P.. (2010) To fight or die - inhibitor of apoptosis proteins at the crossroad of innate immunity and death.. Current opinion in cell biology, [PMID:20888210] |
| 26. Damgaard, Rune B RB and Gyrd-Hansen, Mads M.. (2011) Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and innate immunity.. Discovery medicine, [PMID:21447281] |
| 27. Mei, Yide Y, Hahn, Allison Alcivar AA, Hu, Shimin S and Yang, Xiaolu X.. (2011) The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2.. The Journal of biological chemistry, (14): [PMID:21849505] |
| 28. Bertrand, Mathieu J M MJ and 8 more authors.. (2011) cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4).. PloS one, [PMID:21931591] |
| 29. Darding, M M and Meier, P P.. (2012) IAPs: guardians of RIPK1.. Cell death and differentiation, [PMID:22095281] |
| 30. Zhou, Alicia Y AY and 6 more authors.. (2013) IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex.. Cell reports, (28): [PMID:23453969] |
首页
400-620-6333
